|

Zoldonrasib Clinical Trials

2 actively recruiting trials across 2 locations

No change since July 2026

Pipeline

Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Revolution Medicines, Inc.2

Indications

  • Cancer2
  • Pancreatic Adenosquamous Carcinoma1
  • PDAC1
  • Metastatic Solid Tumors1
  • Pancreatic Adenocarcinoma Metastatic1

Tucson, Arizona1 trial

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

The University of Arizona Cancer Center-North Campus

Phase 3

Los Angeles, California1 trial

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

USC Norris Comprehensive Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.